The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
WITHDRAWN: Phase 1/2 study data of the RNR inhibitor BBI-825 in development for the prevention and treatment of patients with colorectal cancer with BRAF V600E or KRAS G12C mutations and resistance gene amplifications.
 
Rona Yaeger
Consulting or Advisory Role - Loxo@Lilly; Mirati Therapeutics; Revolution Medicines
Research Funding - Boehringer Ingelheim (Inst); Boundless Bio (Inst); Daiichi Sankyo/UCB Japan (Inst); Mirati Therapeutics (Inst); Pfizer (Inst)
 
Sant Chawla
Stock and Other Ownership Interests - AADi; Cellestia Biotech; Counterpoint Biomedica; Immix BioPharma
Honoraria - Advenchen Laboratories; Amgen; Bayer; CytRx Corporation; GlaxoSmithKline; Ignyta; Immune Design; InhibRx; Janssen; Karyopharm Therapeutics; NKMax; Roche; Sarcoma Alliance for Research Through Collaboration SARC); Threshold Pharmaceuticals; Thyme Care; TRACON Pharma
Consulting or Advisory Role - Advenchen Laboratories; Amgen; Bayer; CytRx Corporation; GlaxoSmithKline; Ignyta; Immune Design; InhibRx; Janssen; Karyopharm Therapeutics; NKMax; Roche; SARC: Sarcoma Alliance for Research though Collaboration; Threshold Pharmaceuticals; Thyme Care; TRACON Pharma
Speakers' Bureau - Advenchen Laboratories; Amgen; Bayer; CytRx Corporation; GlaxoSmithKline; Ignyta; Immune Design; InhibRx; Janssen; Karyopharm Therapeutics; NKMax; Roche; SARC: Sarcoma Alliance for Research though Collaboration; Threshold Pharmaceuticals; Thyme Care; TRACON Pharma
 
Ildefonso Rodriguez Rivera
Employment - Next Oncology; Texas Oncology
Stock and Other Ownership Interests - Next Oncology; Texas Oncology
Consulting or Advisory Role - Cardinal Health; Syneos Health; Telix Pharmaceuticals; Werewolf Therapeutics
 
Manish Sharma
Stock and Other Ownership Interests - Abbott Laboratories; Abbvie; Amgen; Bristol-Myers Squibb; Gilead Sciences; Johnson & Johnson/Janssen; Lilly; Merck; Moderna Therapeutics; Pfizer; Regeneron; Vertex; West Pharmaceutical
Consulting or Advisory Role - Pliant
Research Funding - Abbvie (Inst); Adcentrx Therapeutics (Inst); Agenus (Inst); Alkermes (Inst); Alpine Immune Sciences (Inst); ALX Oncology (Inst); Artios (Inst); Astellas Pharma (Inst); AstraZeneca (Inst); Black Diamond Therapeutics (Inst); Boehringer Ingelheim (Inst); Bolt Biotherapeutics (Inst); Boundless Bio Therapeutics (Inst); Bristol-Myers Squibb (Inst); Celgene (Inst); Chugai Pharma (Inst); Compugen (Inst); Cullinan Oncology (Inst); Debiopharm Group (Inst); Deciphera (Inst); eFFECTOR Therapeutics (Inst); Elevation Oncology (Inst); Exelixis (Inst); Genmab (Inst); Gilead Sciences (Inst); GlaxoSmithKline/Tesaro (Inst); Helsinn Therapeutics (Inst); IgM Biosciences (Inst); Ikena Oncology (Inst); Incyte (Inst); InhibRx (Inst); Johnson & Johnson/Janssen (Inst); Johnson & Johnson/Janssen (Inst); Jounce Therapeutics (Inst); Kinnate Biopharma (Inst); KLUS Pharma (Inst); KSQ Therapeutics (Inst); Loxo (Inst); Macrogenics (Inst); Merck (Inst); Mersana (Inst); Mirati Therapeutics (Inst); NGM Biopharmaceuticals (Inst); Onconova Therapeutics (Inst); Palleon Pharmaceuticals (Inst); Pfizer (Inst); Pliant (Inst); PureTech (Inst); Qualigen Therapeutics (Inst); Regeneron (Inst); Repare Therapeutics (Inst); Sapience Therapeutics (Inst); Seagen (Inst); Seven and Eight Biopharmaceuticals (Inst); Shattuck Labs (Inst); SK Life Sciences (Inst); Symphogen (Inst); Syros Pharmaceuticals (Inst); Tempest Therapeutics (Inst); Theratechnologies (Inst); Tizona Therapeutics, Inc. (Inst); Treadwell Therapeutics (Inst)
 
Ryan Hansen
Employment - Boundless Bio
Stock and Other Ownership Interests - Boundless Bio
Patents, Royalties, Other Intellectual Property - Boundless Bio
 
Sara Weymer
Employment - Boundless Bio
Leadership - Boundless Bio
Stock and Other Ownership Interests - Boundless Bio
Travel, Accommodations, Expenses - Boundless Bio
 
Klaus Wagner
Employment - Boundless Bio
Leadership - Boundless Bio
Stock and Other Ownership Interests - Boundless Bio
Patents, Royalties, Other Intellectual Property - Boundless Bio
 
Shiraj Sen
Employment - Roche/Genentech
Stock and Other Ownership Interests - Roche/Genentech
Consulting or Advisory Role - Revolution Medicines (Inst); Roche/Genentech (Inst)
Research Funding - ABM (Inst); Arcus Biosciences (Inst); BeiGene (Inst); Centessa Pharmaceuticals (Inst); Cullinan Oncology (Inst); Dicerna (Inst); Georgiamune (Inst); Gilead Sciences (Inst); IconOVir Bio (Inst); IDEAYA Biosciences (Inst); ImmunoGenesis (Inst); OncoResponse (Inst); Parthenon Therapeutics (Inst); Pyxis (Inst); Pyxis (Inst); Revolution Medicines (Inst); Sensei Biotherapeutics (Inst); Tallac Therapeutics (Inst); Vividion Therapeutics (Inst); Zentalis (Inst)